Tag Archives: Pfizer
Deals Don't Need Science To Be A Success
Deals don’t need science to be a success
By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC
Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy Also tagged Deals, Genentech, integration, mergers. M&A 2 Comments
Pharma's Influence on the Super Committee: Is Cash Really King?
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
Posted in Strategy, healthcare, leadership Also tagged Congress, deficit, Eli Lilly, PhRMA, Politics, Super Committee 1 Comment
Planning Beyond the Petri Dish: A Pfizer Case Study
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk.
The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D Also tagged Asia, crizotinib, Emerging Markets, Japan, Korea, NSCLC, R&D Leave a comment
Study Points to Dramatic Drop In R&D Expenditure
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook.
The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D Also tagged GSK, Pharmaceutical Factbook, R&D, Thomson Reuters 1 Comment

UK Reacts to AZ Job Cuts